JP Morgan Chase’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,134,753
| Closed | -$67.1M | – | 7806 |
|
|
2026
Q1 | $67.1M | Buy |
3,134,753
+3,091,223
| +7,101% | +$43.6M | ﹤0.01% | 1205 |
|
|
2025
Q4 | $406K | Sell |
43,530
-22,152
| -34% | -$185K | ﹤0.01% | 5162 |
|
|
2025
Q3 | $463K | Sell |
65,682
-23,420
| -26% | -$161K | ﹤0.01% | 5082 |
|
|
2025
Q2 | $579K | Buy |
89,102
+27,566
| +45% | +$190K | ﹤0.01% | 4697 |
|
|
2025
Q1 | $488K | Buy |
61,536
+1,109
| +2% | +$11.9K | ﹤0.01% | 4793 |
|
|
2024
Q4 | $766K | Sell |
60,427
-556
| -0.9% | -$7.74K | ﹤0.01% | 4801 |
|
|
2024
Q3 | $849K | Buy |
60,983
+530
| +0.9% | +$7.56K | ﹤0.01% | 4572 |
|
|
2024
Q2 | $833K | Sell |
60,453
-10,756
| -15% | -$157K | ﹤0.01% | 4384 |
|
|
2024
Q1 | $1.18M | Sell |
71,209
-33,587
| -32% | -$503K | ﹤0.01% | 4227 |
|
|
2023
Q4 | $1.53M | Buy |
104,796
+13,270
| +14% | +$161K | ﹤0.01% | 4029 |
|
|
2023
Q3 | $1.12M | Buy |
91,526
+23,942
| +35% | +$312K | ﹤0.01% | 3983 |
|
|
2023
Q2 | $807K | Buy |
67,584
+45,373
| +204% | +$593K | ﹤0.01% | 4208 |
|
|
2023
Q1 | $297K | Sell |
22,211
-49,795
| -69% | -$973K | ﹤0.01% | 4815 |
|
|
2022
Q4 | $1.55M | Sell |
72,006
-5,308
| -7% | -$109K | ﹤0.01% | 3753 |
|
|
2022
Q3 | $1.55M | Buy |
77,314
+60,799
| +368% | +$1.29M | ﹤0.01% | 3673 |
|
|
2022
Q2 | $295K | Sell |
16,515
-4,436
| -21% | -$45.8K | ﹤0.01% | 4867 |
|
|
2022
Q1 | $208K | Sell |
20,951
-31,009
| -60% | -$410K | ﹤0.01% | 5171 |
|
|
2021
Q4 | $875K | Buy |
51,960
+47,737
| +1,130% | +$981K | ﹤0.01% | 4488 |
|
|
2021
Q3 | $100K | Buy |
4,223
+4,169
| +7,720% | +$99.9K | ﹤0.01% | 5565 |
|
|
2021
Q2 | $1K | Buy |
+54
| New | +$1.13K | ﹤0.01% | 6238 |
|
Other funds holding DAWN
JP Morgan Chase's DAWN Position: Q2 2026 in Review
JP Morgan Chase sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 3,134,753 shares — an estimated $67.1M sold.
JP Morgan Chase first reported a position in DAWN in Q2 2021 and held it in 20 quarters. The position peaked at $67.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- JP Morgan Chase reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 3,134,753 Day One Biopharmaceuticals shares in Q2 2026, an estimated $67.1M.
- JP Morgan Chase first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 20 quarters.
- JP Morgan Chase's Day One Biopharmaceuticals position peaked at $67.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.